Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation Sixty-five empirical papers were ...
To identify the strongest variable(s) linked with the number of ranibizumab injections and outcomes in AURA, and to identify ways to improve outcomes using this association. Data were analyzed from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results